This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Tofogliflozin
- DrugBank Accession Number
- DB11824
- Background
Tofogliflozin has been used in trials studying the treatment and prevention of Diabetes Mellitus Type 2.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Tofogliflozin (DB11824)
- Weight
- Average: 386.444
Monoisotopic: 386.172938557 - Chemical Formula
- C22H26O6
- Synonyms
- Tofogliflozin
- Tofogliflozin anhydrous
- External IDs
- CSG 452
- CSG-452
- R-7201
- RO-4998452
- RO4998452
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The risk or severity of hypoglycemia can be increased when Acarbose is combined with Tofogliflozin. Acebutolol The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Acebutolol. Acetazolamide The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Acetazolamide. Acetohexamide The risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Tofogliflozin. Acetyl sulfisoxazole The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Acetyl sulfisoxazole. Acetylsalicylic acid The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Tofogliflozin. Albiglutide The risk or severity of hypoglycemia can be increased when Albiglutide is combined with Tofogliflozin. Alclometasone The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Tofogliflozin. Alogliptin The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Tofogliflozin. Amcinonide The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Tofogliflozin. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Tofogliflozin hydrate P8DD8KX4O4 1201913-82-7 ZXOCGDDVNPDRIW-NHFZGCSJSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as isocoumarans. These are compounds containing the coumaran skeleton, which consists of a benzene ring fused to a 1,3-dihydrofuran ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Isocoumarans
- Sub Class
- Not Available
- Direct Parent
- Isocoumarans
- Alternative Parents
- Isobenzofurans / Ketals / Oxanes / Monosaccharides / Benzene and substituted derivatives / Secondary alcohols / Polyols / Oxacyclic compounds / Primary alcohols / Hydrocarbon derivatives
- Substituents
- Acetal / Alcohol / Aromatic heteropolycyclic compound / Benzenoid / Hydrocarbon derivative / Isobenzofuran / Isocoumaran / Ketal / Monocyclic benzene moiety / Monosaccharide
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 554245W62T
- CAS number
- 903565-83-3
- InChI Key
- VWVKUNOPTJGDOB-BDHVOXNPSA-N
- InChI
- InChI=1S/C22H26O6/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22+/m1/s1
- IUPAC Name
- (1S,3'R,4'S,5'S,6'R)-6-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)-3H-spiro[2-benzofuran-1,2'-oxane]-3',4',5'-triol
- SMILES
- CCC1=CC=C(CC2=CC=C3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=C2)C=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 46908929
- PubChem Substance
- 347828171
- ChemSpider
- 28530778
- BindingDB
- 50396779
- ChEBI
- 136041
- ChEMBL
- CHEMBL2110731
- ZINC
- ZINC000035826342
- Wikipedia
- Tofogliflozin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD 1 4 Completed Treatment Type 2 Diabetes Mellitus 2 2 Completed Treatment Type 2 Diabetes Mellitus 1 2 Recruiting Treatment Metformin / SGLT2-Inhibitors / Type 2 Diabetes Mellitus 1 2 Recruiting Treatment Nash 1 1 Completed Prevention Type 2 Diabetes Mellitus 1 1 Completed Supportive Care Healthy Subjects (HS) 1 1 Completed Treatment Healthy Subjects (HS) 1 1 Completed Treatment Type 2 Diabetes Mellitus 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.327 mg/mL ALOGPS logP 1.5 ALOGPS logP 2.47 Chemaxon logS -3.1 ALOGPS pKa (Strongest Acidic) 12 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 99.38 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 103.33 m3·mol-1 Chemaxon Polarizability 41.48 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 20:51 / Updated at February 21, 2021 18:53